

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

ATH 108 CON1

Sheet	1	of	3
-------	---	----	---

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	5,035,878		Borsch	07-30-1991	
	AB	5,155,250		Parker	10-13-1992	
	AC	5,262,439		Parthasarathy	11-16-1993	
	AD	5,294,430		Borsch	03-15-1994	
	AE	5,608,095		Parker et al.	03-04-1997	

[illegible]

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.**

Please type a plus sign (+) inside this box +


PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <div style="text-align: center; font-weight: bold; font-size: 1.2em;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT </div> <div style="text-align: center; font-size: 0.8em; margin-top: 10px;"> <i>(use as many sheets as necessary)</i> </div>				Complete if Known	
		Application Number			
		Filing Date	2/7/01		
		First Named Inventor	Chinery		
		Group Art Unit			
		Examiner Name			
		Attorney Docket Number	ATH 108 CON1		
Sheet	2	of	3		



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	BA	COFFEY, et al., <i>Cancer Res.</i> 47, 4590 (1987)	
	BB	CROOK, et al. <i>Oncogene</i> 6, 873 (1991)	
	BC	SCHEFFNER, et al. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88, 5523 (1991)	
	BD	RIPOLL, et al., Vitamin E Enhances the Chemotherapeutic Effects of Adriamycin, <i>Biological Abstracts</i> , 82, 82084938	
	BE	YAUNAGA et al., Vitamin E and Cancer Therapy-Experimental Study in Mice, Database National Cancer Institute, 1982.	
	BF	SZCZEPANSKA et al., Inhibition of Leukocyte Migration by Cancer Chemotherapeutic Agents and its Prevention by Free Radical Scavengers and Thiols, <i>Biological Abstracts</i> Vol. 85, 85106445	
	BG	PRASAD et al., Vitamin E Increases the Growth Inhibitory and Differentiating Effects of Tumor Therapeutic Agents on Neuro Blastoma and Glioma Cells in Culture, <i>Biological Abstracts</i> , vol. 70, 70052454	
	BH	DRAGO, et al., Chemotherapy and Vitamin E in Treatment of NB Rat Prostrate Tumors, <i>Biological Abstracts</i> Vol. 88, 88006807	
	BI	CLOOS JACQUELINE JAN, Influence of the antioxidant N-acetylcysteine and its metabolites on Damage induced by Bleomycin in PM2 Bacteriophage, <i>Biological Abstracts</i> , Vol. 96, 98730849.	
	BJ	RIORDAN et al., Case study: High Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney, <i>J. Orthomolecular Med.</i> , 5:1, 1990, 5-7.	
	BK	CAMPBELL et al., Reticulum Cell Sarcoma: Two Complete "Spontaneous" Regressions, in Response to High-Dose Ascorbic Acid Therapy, <i>Oncology</i> , 48: 6 (1991), 495-497.	
	BL	BONGERS, Antioxidant-Related Parameters in Patients Treated for Cancer Chemoprevention with N-acetylcysteine, <i>Biological Abstracts</i> , vol. 95, 98363146.	
	BM	OFFERMAN, et al. Antioxidant Sensitive Regulation of Inflammatory Response Genes in Kaposi's Sarcoma Cells, <i>J. of AIDS and Hum. Retro.</i> , (1996) 13:1-11.	
	BN	TYAGI S C, Reduction-Oxidation state Regulation of Extracellular Matrix Metalloproteinases and Tissue Inhibitors in Cardiac Normal and Transformed Fibroblast Cells, <i>Biological Abstracts</i> , vol. 96, 98730849.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

+

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT </div> (use as many sheets as necessary)				Comple t if Known	
				Application Number	
				Filing Date	2/7/01
				First Named Inventor	Chinery
				Group Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	ATH 108 CON1

[illegible]

Examiner		Date	
----------	--	------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.**